OVERVIEW

Evaluating the Role of PI3K Inhibitors in Follicular Lymphoma: Highlighting the Diversity and Impact of an Emerging Therapeutic Class is organized by Healthcare Made Practical (HMP) Communications LLC and will be held from Oct 31, 2018 - Oct 31, 2019.

Target Audience:
Designed for hematologists and hematologic oncologists, medical, radiation, and surgical oncologists, and other healthcare professionals (e.g., physicians, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants) who are involved and/or interested in the treatment of patients with hematologic malignancies.

Accreditation:
CME:
NACCME designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™.

Physican Assistants:

NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 0.75 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 credit(s).

CNE
This continuing nursing education activity awards 0.75 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 0.75 contact hours.

CPE
This knowledge-based activity (JA0006201-9999-18-209-H01-P) is approved for 0.75 contact hours (0.0075 CEUs) of continuing pharmacy education.

Course Overview:
Recently, phosphoinositide 3-kinase (PI3K) inhibitors have emerged as a viable therapeutic class in relapsed/refractory FL. The prototypical PI3K inhibitor idelalsib as well as the newer agent copanlisib are now approved in this setting, and other PI3K inhibitors are in various stages of clinical development. However, these agents differ significantly in terms of their specificity for PI3K isoforms; adverse effect profiles; dosing and administration; and efficacy, safety, and tolerability in the management of FL. Thus, healthcare providers must be equipped with a thorough understanding of the within-class distinctions among PI3K inhibitors as well as the clinical data surrounding their use in FL, to make informed therapeutic decisions in relapsed/refractory FL management.

This on-demand web archive is initiated to address knowledge and practice gaps among physicians, NPs, and PAs pertaining to various treatment options in FL.

Course Objectives:
• Highlight the clinical challenges posed by standard chemo-immunotherapeutic approaches to relapsed/refractory FL
• Distinguish among available and emerging PI3K inhibitors with respect to their isoform specificity, associated adverse effect profiles, dosing and administration, and clinical efficacy, safety, and tolerability in the management of FL
• Integrate the latest clinical data, agent-specific considerations, and adverse effect management strategies into FL treatment plans that incorporate the use of PI3K inhibitors as appropriate

Additional details will be posted as soon as they are available.